Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Por um escritor misterioso
Descrição
Frontiers Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
Management of metastatic cutaneous melanoma: updates in clinical practice - Gustavo Schvartsman, Patricia Taranto, Isabella C. Glitza, Sanjiv S. Agarwala, Michael B. Atkins, Antonio C. Buzaid, 2019
Combination immunotherapy shrinks metastatic brain cancer
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
